Quest Diagnostics Incorporated Financial Statements (DGX)
|
|
|
|
Report date
|
|
|
31.12.2022 |
21.02.2023 |
22.02.2024 |
20.02.2025 |
26.02.2026 |
|
22.04.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
9 883 |
9 883 |
9 252 |
9 872 |
11 035 |
|
11 278 |
|
Operating Income, bln rub |
|
|
1 428 |
1 428 |
1 262 |
1 346 |
1 603 |
|
1 614 |
|
EBITDA, bln rub |
? |
|
1 785 |
1 820 |
1 732 |
1 894 |
2 194 |
|
1 980 |
|
Net profit, bln rub |
? |
|
946.0 |
946.0 |
854.0 |
871.0 |
992.0 |
|
1 024 |
|
|
OCF, bln rub |
? |
|
1 718 |
1 718 |
1 272 |
1 334 |
1 886 |
|
1 850 |
|
CAPEX, bln rub |
? |
|
404.0 |
404.0 |
408.0 |
425.0 |
527.0 |
|
524.0 |
|
FCF, bln rub |
? |
|
1 314 |
1 314 |
864.0 |
909.0 |
1 359 |
|
1 326 |
|
Dividend payout, bln rub
|
|
|
305.0 |
305.0 |
314.0 |
331.0 |
353.0 |
|
357.0 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
32.2% |
32.2% |
36.8% |
38.0% |
35.6% |
|
34.9% |
|
|
OPEX, bln rub |
|
|
1 874 |
2 005 |
1 807 |
1 898 |
1 920 |
|
2 134 |
|
Cost of production, bln rub |
|
|
0.000 |
6 450 |
6 199 |
6 628 |
7 512 |
|
7 530 |
|
R&D, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
138.0 |
148.0 |
163.0 |
226.0 |
264.0 |
|
265.0 |
|
|
Assets, bln rub |
|
|
12 837 |
12 837 |
14 022 |
16 153 |
16 225 |
|
16 673 |
|
Net Assets, bln rub |
? |
|
5 893 |
5 893 |
6 307 |
6 778 |
7 170 |
|
7 366 |
|
Debt, bln rub |
|
|
4 775 |
4 714 |
5 498 |
7 087 |
6 919 |
|
6 980 |
|
Cash, bln rub |
|
|
315.0 |
315.0 |
686.0 |
549.0 |
420.0 |
|
393.0 |
|
Net debt, bln rub |
|
|
4 460 |
4 399 |
4 812 |
6 538 |
6 499 |
|
6 587 |
|
|
Ordinary share price, rub |
|
|
156.4 |
156.4 |
137.9 |
150.9 |
173.5 |
|
187.5 |
|
Number of ordinary shares, mln |
|
|
116.0 |
116.0 |
112.0 |
111.0 |
111.0 |
|
110.0 |
|
|
Market cap, bln rub |
|
|
18 147 |
18 147 |
15 443 |
16 745 |
19 262 |
|
20 623 |
|
EV, bln rub |
? |
|
22 607 |
22 546 |
20 255 |
23 283 |
25 761 |
|
27 210 |
|
Book value, bln rub |
|
|
-2 419 |
-2 419 |
-2 592 |
-3 841 |
-3 411 |
|
-3 471 |
|
|
EPS, rub |
? |
|
8.16 |
8.16 |
7.63 |
7.85 |
8.94 |
|
9.31 |
|
FCF/share, rub |
|
|
11.3 |
11.3 |
7.71 |
8.19 |
12.2 |
|
12.1 |
|
BV/share, rub |
|
|
-20.9 |
-20.9 |
-23.1 |
-34.6 |
-30.7 |
|
-31.6 |
|
|
EBITDA margin, % |
? |
|
18.1% |
18.4% |
18.7% |
19.2% |
19.9% |
|
17.6% |
|
Net margin, % |
? |
|
9.57% |
9.57% |
9.23% |
8.82% |
8.99% |
|
9.08% |
|
FCF yield, % |
? |
|
7.24% |
7.24% |
5.59% |
5.43% |
7.06% |
|
6.43% |
|
ROE, % |
? |
|
16.1% |
16.1% |
13.5% |
12.9% |
13.8% |
|
13.9% |
|
ROA, % |
? |
|
7.37% |
7.37% |
6.09% |
5.39% |
6.11% |
|
6.14% |
|
|
P/E |
? |
|
19.2 |
19.2 |
18.1 |
19.2 |
19.4 |
|
20.1 |
|
P/FCF |
|
|
13.8 |
13.8 |
17.9 |
18.4 |
14.2 |
|
15.6 |
|
P/S |
? |
|
1.84 |
1.84 |
1.67 |
1.70 |
1.75 |
|
1.83 |
|
P/BV |
? |
|
-7.50 |
-7.50 |
-5.96 |
-4.36 |
-5.65 |
|
-5.94 |
|
EV/EBITDA |
? |
|
12.7 |
12.4 |
11.7 |
12.3 |
11.7 |
|
13.7 |
|
Debt/EBITDA |
|
|
2.50 |
2.42 |
2.78 |
3.45 |
2.96 |
|
3.33 |
|
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
CAPEX/Revenue, % |
|
|
4.09% |
4.09% |
4.41% |
4.31% |
4.78% |
|
4.65% |
|
| Quest Diagnostics Incorporated shareholders |
